HOWL earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -0.30. Updated 2026-07-23.
Werewolf Therapeutics (HOWL) Research Hub
Werewolf Therapeutics (HOWL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 0.982 USD (+1.76%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.30, market cap 0.02B. This hub links to the full technical, earnings and options research available for HOWL.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.982 USD (+1.76%) |
| 52-week range | 0.295 USD – 1.05 USD |
| Trend regime | Range |
| 14-day RSI | 88.5 (Overbought) |
| Trailing P/E | -0.30 |
| Market cap | 0.02B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for HOWL
Covered Call on HOWL: how it works, illustrative setup around the real 0.982 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on HOWL: how it works, illustrative setup around the real 0.982 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on HOWL: how it works, illustrative setup around the real 0.982 USD price, max profit/loss, breakeven and when to use it. Educational.
HOWL technical analysis: range, last 0.982 USD, RSI 88.5, 52w range 0.295 USD–1.05 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is HOWL in?
Werewolf Therapeutics (HOWL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is HOWL in an uptrend or downtrend?
As of 2026-09-11, HOWL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is HOWL's trailing P/E ratio?
HOWL's trailing P/E is -0.30, with a market cap of 0.02B. See the earnings research page for full valuation detail.
When does HOWL next report earnings?
HOWL is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.28 USD.